 |
For trials in either Phase II, Phase
III or in transition: |
| |
– What are essential results? |
| |
– How are they dealing with anticipated
side effect? |
| |
– What kind of patient population enrolled? |
| |
– What is dosing protocol |
| |
– Do they have trials arms for X, for
Y and/or Z? |
|
Going for indications or just clinical
pharmacology mentions? |
